A novel in vitro model of thyroid ophthalmopathy

一种新型的甲状腺眼病体外模型

基本信息

  • 批准号:
    6889867
  • 负责人:
  • 金额:
    $ 15.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-05-01 至 2007-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Thyroid-associated ophthalmopathy (TAO) is the most commonly encountered orbital disease, affecting vision and producing disfigurement. We are beginning to explore an in vitro model of TAO based upon a new methodology of reverse autologous mixed cell reaction (rAMCR), which studies the effects of autologous T-cells from TAO patients on DNA synthesis in orbital fibroblasts from the same patient. This investigation that should meet the NEI challenge to "yield insight into the initiating events leading to fibroblast activation and tissue remodeling and the cell signaling events that stimulate the trafficking of immunocompetent cells to the orbit". It should also aid in determining the immunologic and hormonal basis for the proliferation and phenotypic alteration of orbital fibroblasts (OF). The purpose of this R03 pilot study application is to further develop this model, including a rigorous evaluation of the immunologic and local environmental mechanisms involved in the enhancement of orbital fibroblast proliferation in the rAMCR. The overall hypothesis to be tested in this proposal is that peripheral blood from TAO patients contains T cells that directly activate OF to enhance fibroproliferation and to drive OF to an activated phenotype and to adipocyte-like cells characteristic of TAO. The two specific aims of the study are to determine 1) which subset(s) of peripheral blood T cells are key for stimulating OF proliferation and activation in vitro and by which means of cell-cell communication is this accomplished? and 2) what are the key functional consequences of activation by peripheral blood T cells? In preliminary studies, we have shown that an enriched T-cell results in a two-to-three fold HLA DRII and CD40/CD 40 ligand dependent increase in fibroproliferation. Understanding which OF subset is the target of the rAMCR will help narrow the avenues for therapeutic exploration and will define the cellular cross-talk between immune cells and OF. The nature of the OFs is of critical importance in TAO as they are the effector cells that cause the tissue pathology, including the accumulation of fatty tissue (especially early in disease) and the muscle fibrosis that occurs later. Exploration of the rAMCR model will help move the TAO field forward and will lead to new insights into the pathophysiology of the disease and identification of target molecules the may serve as a basis for possible therapeutic intervention.
描述(由申请人提供):甲状腺相关眼病(TAO)是最常见的眼眶疾病,影响视力并造成毁容。 我们开始探索一种基于反向自体混合细胞反应(rAMCR)的新方法的TAO体外模型,该方法研究了TAO患者的自体T细胞对同一患者眼眶成纤维细胞DNA合成的影响。 这项研究应该满足NEI的挑战,即“深入了解导致成纤维细胞活化和组织重塑的起始事件以及刺激免疫活性细胞向眼眶运输的细胞信号传导事件”。 它还应有助于确定眼眶成纤维细胞(OF)增殖和表型改变的免疫学和激素基础。 本R 03初步研究申请的目的是进一步开发该模型,包括严格评价rAMCR中眼眶成纤维细胞增殖增强所涉及的免疫学和局部环境机制。 在该提议中待检验的总体假设是,来自TAO患者的外周血含有直接激活OF以增强纤维增殖并将OF驱动至活化表型和TAO特征的脂肪细胞样细胞的T细胞。 本研究的两个具体目的是确定1)外周血T细胞的哪些亚群是体外刺激OF增殖和活化的关键,以及通过何种细胞间通讯实现?以及2)外周血T细胞激活的关键功能后果是什么?在初步研究中,我们已经表明,富集的T细胞导致纤维增殖中的2 - 3倍HLA DRII和CD 40/CD 40配体依赖性增加。 了解哪一个OF亚群是rAMCR的靶点将有助于缩小治疗探索的途径,并将定义免疫细胞和OF之间的细胞串扰。 OFs的性质在TAO中至关重要,因为它们是引起组织病理学的效应细胞,包括脂肪组织的积累(特别是在疾病早期)和随后发生的肌肉纤维化。rAMCR模型的探索将有助于推动TAO领域的发展,并将导致对疾病病理生理学的新见解和靶分子的鉴定,这些分子可能作为可能的治疗干预的基础。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven E Feldon其他文献

Steven E Feldon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven E Feldon', 18)}}的其他基金

A novel in vitro model of thyroid ophthalmopathy
一种新型的甲状腺眼病体外模型
  • 批准号:
    6597233
  • 财政年份:
    2003
  • 资助金额:
    $ 15.75万
  • 项目类别:
A novel in vitro model of thyroid ophthalmopathy
一种新型的甲状腺眼病体外模型
  • 批准号:
    6739001
  • 财政年份:
    2003
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    2838321
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    2387173
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    3559919
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    2163172
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    2163171
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    2163170
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    2608630
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:
ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL
缺血性视神经病变减压试验
  • 批准号:
    3559920
  • 财政年份:
    1992
  • 资助金额:
    $ 15.75万
  • 项目类别:

相似海外基金

The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
  • 批准号:
    DP240102905
  • 财政年份:
    2024
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23K28188
  • 财政年份:
    2024
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
  • 批准号:
    2339172
  • 财政年份:
    2024
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
  • 批准号:
    10577518
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23H03498
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
  • 批准号:
    10676407
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
  • 批准号:
    22KK0277
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
  • 批准号:
    10599584
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
  • 批准号:
    10530023
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
  • 批准号:
    10684172
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了